diagnost tool
deliv lot news flow lot
easi guid report bounce-back revenue beat record
near goodwil impair charg cyno last quarter hard us
declar fxn revenue growth rate victori miss us/th street
gross oper margin line geograph mix shift faster grow ou rev
initi guid street part due view cyno
declin q/q expect impact mona lisa touch recent fda warn
letter net net reiter hold concern may struggl achiev
aspir target mid-singl digit growth coupl margin concern
reiter pt use multipl adj ep
cfo switch cfo bob mcmahon leav becom cfo market
cap agil rate replac karleen oberton cao
time switch ideal close impair cynosur
think miss bob mcmahon overli concern news
 announc acquir faxitron bioptic rev
rev view complementari tuck-in breast health franchis
strength rev ex cyno grew fxn total ou rev grew
y/i fxn driven y/i ou breast health ou fxn
dx growth new product launch peform drove
placement panther dx util rise leverag ratio
challeng declin gm om unclear level om expans
us revenu declin y/i mona lisa touch cyno rev warn
letter pose addit uncertainti cyno uncertain growth rate
cyno rev y/i achiev compani goal q/q growth beat
ceo macmillan indic first time
normal level salesforc encourag guid cyno declin q/
 summer soft dip mona lisa touch cyno rev
gm pressur adj gm y/i miss street
due mix higher sale lower-margin ou cyno product lower rev
higher margin surgic product flat y/i fxn
deliv revenue ep beat rev fxn beat
street adj ep beat our/street deliv beat vs
model follow breast health diagnost segment
roughli in-lin adj om y/i miss our/street
guid revenue beat rais revenue guid
adj ep guid
guid rev prior
adj ep vs prior
us next week boston pleas host investor dinner
mistral boston next tue follow firesid chat wed
annual canaccord genuiti growth confer pleas contact us attend
price close busi juli
global leader diagnost breast
imag surgic product focu women
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
aspir target contempl setup
comment detail prepar guid next year
commun hope mid-singl digit revenu growth target well goal
double-digit growth medic aesthet return mid-singl digit growth
 bolt faxitron bioptic concur earn releas
even announc acquisit complet acquisit privately-held
faxitron bioptic rev rev manag indic
call compani growth rate exce compani averag
would quantifi specif growth rate margin unclear double-
digit grower faxitron bioptic certainli bolt-on varieti report
compani breast health busi add revenu
model reflect month contribut quarter given acquisit
close today juli faxitron bioptic lead provid digit specimen
radiographi believ complement exist portfolio indic
faxitron product enabl better particp breast conserv
surgeri view adjac growth market intervent breast
busi one faxitron product includ visionct world first breast
specimen-design ct system offer imag excis lesion
expect acquisit roughli neutral adj ep
itc initi rule help keep fuji away end breast health
market earlier week alj us intern trade commiss itc issu
favor initi rule vs fuji complaint alleg fuji
violat ip relat market lead tomo breast imag product judg
recommend exclus order prevent import cease-and-desist order
prevent sale market infring product part
initi rule judg rule fuji infring patent brought trial
reject fuji defens patent final rule itc schedul
issu novemb expect judg initi rule turn final later
year margin help keep fuji bay low end market
estim fuji less market perhap less
breast health segment standout perform breast health revenu
came report fxn
driven strong growth ou ou fxn partial
off-set growth rate us busi drove y/i growth
intervent breast product driven growth brevera biopsi affirm prone
us ou molecular diagnost total ou rev grew solid y/i fxn
ex-cyno us sale rev slightli y/i diagnost
revenu ex-blood grew fxn driven fxn growth molecular
cyno recal prior quarter record surpris goodwil
impair charg cynosur paid net cash
last quarter indic two-third us cyno salesforc new
last year mani new last day impli departur
tenur new leader kevin thornal indic made good
progress fill open vacanc expect rep take month fulli ramp
model larg move line light guid rel street
expect lower rev even though
ad new acquisit reiter adj
ep vs guid rais rev
larg reflect strong beat rais
adj ep part carri forward beat rais
rev y/i bake acquir
faxitron bioptic busi revenu partial off-set modest
put take segment rais adj ep estim
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
diagnost tool
